Latest news with #COMPASSPathways
Yahoo
17-07-2025
- Business
- Yahoo
Cathie Wood's ARK Adds 125K COMPASS Pathways plc (CMPS) Shares
COMPASS Pathways plc (NASDAQ:CMPS) is among the . ARK Invest's ETFs, led by Cathie Wood, disclosed their daily trades on Thursday with the purchase of 125,491 shares of COMPASS Pathways plc (NASDAQ:CMPS), worth around $424,159. This transaction adds to the consistent buys in CMPS in the last few days, implying confidence in the company's prospects. Just recently, COMPASS Pathways plc (NASDAQ:CMPS) announced the success of its Phase 3 COMP005 trial for COMP360 in meeting its primary endpoint in patients with treatment-resistant depression. As the results outlined, even a single dose of 25 mg COMP360 led to a statistically significant reduction in symptom severity in contrast to placebo at week 6. A patient undergoing psilocybin therapy in a modern clinic, showing the cutting-edge mental health treatment. The company's future looks equally promising, with the management working to discuss the preliminary COMP005 data with the U.S. Food and Drug Administration. Although there is no update regarding the review of the results yet, COMPASS Pathways plc (NASDAQ:CMPS) expects to reveal 26-week data for COMP005, after the participants have passed the initial stage, by the end of 2026. COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company that specializes in mental health across the United States and the UK. Founded in 2020, the company is committed to making evidence-based innovation in mental health accessible to all. While we acknowledge the potential of CMPS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . While we acknowledge the potential of CMPS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CMPS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
30-06-2025
- Health
- Globe and Mail
Post-Traumatic Stress Disorder Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Post-Traumatic Stress Disorder (PTSD) Pipeline Insight, 2025,' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Post-Traumatic Stress Disorder (PTSD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Post-Traumatic Stress Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Post-Traumatic Stress Disorder Treatment Landscape. Click here to read more @ Post-Traumatic Stress Disorder Pipeline Outlook Key Takeaways from Post-Traumatic Stress Disorder Pipeline Report In June 2025, COMPASS Pathways announced a study of Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder. In June 2025, Otsuka Pharmaceutical Development & Commercialization Inc. announced a study of 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult participants with Post-Traumatic Stress Disorder. In June 2025, Lykos Therapeutics conducted a study is a randomized, double-blind, dose comparison study with an open-label cross-over segment that will assess the safety and efficacy of MDMA-assisted therapy in veterans with chronic PTSD. Twelve of 24 participants will receive the full dose of 125 mg, six will receive 75 mg and six will receive 30 mg (active placebo dose) of MDMA HCl. An independent rater blind to condition will assess symptoms of PTSD and depression, general quality of life and posttraumatic growth prior to any therapy sessions one month after the second experimental session. DelveInsight's Post-Traumatic Stress Disorder pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Post-Traumatic Stress Disorder treatment. The leading Post-Traumatic Stress Disorder Companies such as Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others. Promising Post-Traumatic Stress Disorder Pipeline Therapies such as Sertraline and Risperidone, Balovaptan, Brexpiprazole, Psilocybin, JZP150c, Vortioxetine, NYX-783, BNC210, Orvepitant and others. Discover groundbreaking developments in Post-Traumatic Stress Disorder Therapies! Gain in-depth knowledge of key Post-Traumatic Stress Disorder clinical trials, emerging drugs, and market opportunities @ Post-Traumatic Stress Disorder Clinical Trials Assessment Post-Traumatic Stress Disorder Emerging Drugs Profile TNX-102: Tonix Pharmaceuticals, Inc. TNX-102 SL is a small, rapidly-disintegrating, under the tongue (sublingual) product candidate containing cyclobenzaprine HCl. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality, while minimizing the potential residual effects of oral formulations of cyclobenzaprine. As a multifunctional agent with potent binding and antagonist activities at the serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors, TNX-102 SL is in clinical development and has active IND's as a daily bedtime treatment for fibromyalgia, PTSD, alcohol use disorder and agitation in Alzheimer's disease (AAD). TNX-102 SL for AAD has been designated by the FDA a Fast Track development program. Currently, the drug is in phase III stage for the treatment of post-traumatic stress disorder. Methylone (TSND-201): Transcend Therapeutics Methylone, identified as a rapid-acting neuroplastogen, has been shown to swiftly trigger the expression of neuroplasticity genes, including BDNF, in brain regions associated with the pathophysiology of conditions like PTSD, depression, and other central nervous system disorders. This effect is particularly significant given the challenges posed by PTSD, MDD, and anxiety, which stem from deficiencies in the brain circuitry responsible for emotional learning and processing. Currently, the drug is in Phase II stage of its clinical trial for the treatment of PTSD. BXCL501: BioXcel Therapeutics BXCL501, developed by BioXcel Therapeutics, is an innovative neuroscience clinical asset with a novel mechanism of action targeting symptoms like agitation. This investigational, proprietary, orally dissolving film formulation contains dexmedetomidine, a selective alpha-2 receptor agonist. BXCL501 aims to address stress-related behaviors such as agitation and has shown promising anti-agitation results in various clinical trials across neuropsychiatric disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of PTSD. The Post-Traumatic Stress Disorder Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment. Post-Traumatic Stress Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market Stay informed about the Post-Traumatic Stress Disorder pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Post-Traumatic Stress Disorder Unmet Needs Post-Traumatic Stress Disorder Companies Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others. Post-traumatic stress disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Post-Traumatic Stress Disorder Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Post-Traumatic Stress Disorder Pipeline! See the latest progress in drug development and clinical research @ Post-Traumatic Stress Disorder Market Drivers and Barriers, and Future Perspectives Scope of the Post-Traumatic Stress Disorder Pipeline Report Coverage- Global Post-Traumatic Stress Disorder Companies- Tonix Pharmaceuticals, Inc., Pop Test Oncology LLC, H. Lundbeck A/S, Bionomics Limited, Alto Neuroscience, Transcend Therapeutics and others. Post-Traumatic Stress Disorder Pipeline Therapies- Sertraline and Risperidone, Balovaptan, Brexpiprazole, Psilocybin, JZP150c, Vortioxetine, NYX-783, BNC210, Orvepitant and others. Post-Traumatic Stress Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Post-Traumatic Stress Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Post-Traumatic Stress Disorder Pipeline Analysis Today! @ Post-Traumatic Stress Disorder Drugs and Companies Table of Contents Introduction Executive Summary Post-traumatic Stress Disorder (PTSD) : Overview Pipeline Therapeutics Therapeutic Assessment Post-traumatic Stress Disorder (PTSD) – DelveInsight's Analytical Perspective Late Stage Products (Phase III) TNX-102: Tonix Pharmaceuticals, Inc. Drug profiles in the detailed report….. Mid Stage Products (Phase II) Methylone (TSND-201): Transcend Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) BXCL501: BioXcel Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Post-traumatic Stress Disorder (PTSD) Key Companies Post-traumatic Stress Disorder (PTSD) Key Products Post-traumatic Stress Disorder (PTSD) - Unmet Needs Post-traumatic Stress Disorder (PTSD) - Market Drivers and Barriers Post-traumatic Stress Disorder (PTSD) - Future Perspectives and Conclusion Post-traumatic Stress Disorder (PTSD) Analyst Views Post-traumatic Stress Disorder (PTSD) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: Post-Traumatic Stress Disorder
Business Insider
13-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and GH Research (GHRS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and GH Research (GHRS – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. COMPASS Pathways (CMPS) In a report issued on May 8, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $15.00. The company's shares closed last Monday at $3.91, close to its 52-week low of $2.88. According to Timashev is a 2-star analyst with an average return of -0.5% and a 31.6% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Axsome Therapeutics. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $18.75, representing a 368.8% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $23.00 price target. GH Research (GHRS) RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on May 8 and set a price target of $32.00. The company's shares closed last Monday at $10.16. According to Abrahams ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.0% and a 40.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. Currently, the analyst consensus on GH Research is a Strong Buy with an average price target of $31.43, representing a 199.9% upside. In a report issued on May 9, Guggenheim also maintained a Buy rating on the stock with a $29.00 price target.
Globe and Mail
17-02-2025
- Health
- Globe and Mail
COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market
The Chronic Pulmonary Hypertension market growth is driven by factors like increase in the prevalence of Chronic Pulmonary Hypertension, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Chronic Pulmonary Hypertension market report also offers comprehensive insights into the Chronic Pulmonary Hypertension market size, share, Chronic Pulmonary Hypertension epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Pulmonary Hypertension market size growth forward. Some of the key highlights from the Chronic Pulmonary Hypertension Market Insights Report: Several key pharmaceutical companies, including COMPASS Pathways, Homeostasis Therapeutics, LLC, and others, are developing novel products to improve the Chronic Pulmonary Hypertension treatment outlook. In January 2025, AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for treating pulmonary arterial hypertension (PAH), a rare and life-threatening condition characterized by high blood pressure in the lung arteries, which can lead to right-sided heart failure. In December 2024, Nicox announced that its Denali Phase III trial, assessing the efficacy and safety of NCX470 for patients with open-angle glaucoma or ocular hypertension, has completed enrollment in China, and screening has concluded. In November 2024, MediPrint Ophthalmics revealed the results of its Phase IIb clinical trial for LL-BMT1. The trial utilized a new 3D-printed, drug-eluting contact lens for continuous delivery of bimatoprost and hyaluronic acid, successfully meeting all the Phase IIb endpoints. The prevalence of chronic pulmonary hypertension is expected to rise due to factors such as aging populations, increasing obesity rates, better survival rates among premature infants, environmental influences, genetic factors, improved diagnostics, and a rise in comorbidities. In 2023, the US represented the largest share of diagnosed chronic pulmonary hypertension patients in the 7MM, with 42%, followed by Japan, which accounted for around 16% of cases. Among European countries, the UK had the highest number of cases, representing approximately 11% of the total 7MM cases. In 2023, the chronic pulmonary hypertension market was the largest in the US, with a market size of about USD 15,700 million, a figure expected to grow by 2034. Despite the high prevalence, with around 42,476 thousand cases in the 7MM in 2023, the market for chronic pulmonary hypertension treatment remains limited, with few therapies specifically targeting the condition. However, emerging therapies could significantly impact the market, potentially driving substantial growth. As per DelveInsight analysis, the Chronic Pulmonary Hypertension market is anticipated to witness growth at a considerable CAGR Strategise your business goals by understanding market dynamics @ Chronic Pulmonary Hypertension Market Landscape Chronic Pulmonary Hypertension Overview Chronic pulmonary hypertension is a condition characterized by high blood pressure in the lungs, which places strain on the heart and can lead to severe symptoms like shortness of breath and fatigue. It is classified into five groups: Group 1 includes pulmonary arterial hypertension (PAH), Group 2 is pulmonary hypertension caused by left heart disease, Group 3 is pulmonary hypertension linked to lung diseases and/or hypoxia, Group 4 refers to chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unknown or multifactorial causes. Early detection and proper treatment are essential to improve outcomes and quality of life. Diagnosing chronic pulmonary hypertension involves a combination of clinical assessment, imaging, and specialized tests. Challenges can arise due to the nonspecific nature of the symptoms and the need to differentiate pulmonary hypertension from other cardiovascular and respiratory conditions. Diagnostic methods include echocardiography to evaluate heart function and estimate pulmonary artery pressure, followed by confirmatory tests like right heart catheterization, which directly measures pulmonary artery pressures. Accurate interpretation of results can be challenging, especially in cases where other heart or lung conditions are present, requiring a thorough differential diagnosis. Do you know the treatment paradigms for different countries? Download our Chronic Pulmonary Hypertension Market Sample Report Chronic Pulmonary Hypertension Epidemiology Insights The number of chronic pulmonary hypertension cases in the US is projected to grow at a significant compound annual growth rate (CAGR) by 2034, starting from approximately 17,910 thousand cases in 2023. In Europe, Germany had the highest prevalence of chronic pulmonary hypertension, accounting for 26% of cases, followed by the UK in 2023. Conversely, Spain had the lowest prevalence, with around 15% of the total diagnosed cases of chronic pulmonary hypertension in the same year. Chronic Pulmonary Hypertension Epidemiology Segmentation DelveInsight's Chronic Pulmonary Hypertension market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Pulmonary Hypertension historical patient pools and forecasted Chronic Pulmonary Hypertension patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Pulmonary Hypertension Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into: Chronic Pulmonary Hypertension Prevalence Age-Specific Chronic Pulmonary Hypertension Prevalence Gender-Specific Chronic Pulmonary Hypertension Prevalence Diagnosed and Treatable Cases of Chronic Pulmonary Hypertension Visit for more @ Chronic Pulmonary Hypertension Epidemiological Insights Chronic Pulmonary Hypertension Market Outlook Phosphodiesterase-5 (PDE-5) inhibitors like Sildenafil and Tadalafil help reduce vascular smooth muscle cell proliferation and promote vasodilation. Endothelin receptor antagonists, including Ambrisentan, Bosentan, and Macitentan, counteract vasoconstriction and smooth muscle cell growth in the pulmonary arteries. Commonly used calcium channel blockers, such as Nifedipine, diltiazem, and amlodipine, are recommended for treating Pulmonary Arterial Hypertension (PAH). Prostacyclins like epoprostenol, treprostinil, and iloprost improve functional capacity and survival in PAH patients. Additionally, IP prostacyclin receptor agonists, which activate the prostacyclin pathway, are also used for chronic pulmonary hypertension (PH). Endothelin receptor antagonists reduce endothelin-1 levels, which cause constriction and changes in the pulmonary blood vessels in PAH patients. PDE-5 inhibitors and soluble guanylate cyclase (sGC) stimulators help lower enzyme levels that produce nitric oxide (NO), a substance that relaxes pulmonary blood vessels. By increasing cyclic GMP levels, these drugs promote vasodilation. PDE-5 inhibitors prevent the breakdown of cyclic GMP, while sGC stimulators enhance cyclic GMP production when NO binds to the sGC enzyme, making them effective treatments for PAH. Chronic Pulmonary Hypertension Marketed Drugs ADEMPAS (riociguat): Bayer Chronic Pulmonary Hypertension Emerging Drugs CS1: Cereno Scientific AB Chronic Pulmonary Hypertension Key Companies COMPASS Pathways, Homeostasis Therapeutics, LLC, and others For more information, visit Chronic Pulmonary Hypertension Market Analysis, Patient Pool, and Emerging Therapies Scope of the Chronic Pulmonary Hypertension Market Report: 11 Years Forecast 7MM Coverage Descriptive overview of Chronic Pulmonary Hypertension, causes, signs and symptoms, diagnosis, treatment Comprehensive insight into Chronic Pulmonary Hypertension epidemiology in the 7MM Chronic Pulmonary Hypertension marketed and emerging therapies Chronic Pulmonary Hypertension companies Chronic Pulmonary Hypertension market drivers and barriers Table of Contents: 1 Chronic Pulmonary Hypertension Market Key Comprehensive Insights 2 Chronic Pulmonary Hypertension Market Report Introduction 3 Competitive Intelligence Analysis for Chronic Pulmonary Hypertension 4 Chronic Pulmonary Hypertension Market Analysis Overview at a Glance 5 Executive Summary of Chronic Pulmonary Hypertension 6 Chronic Pulmonary Hypertension Epidemiology and Market Methodology 7 Chronic Pulmonary Hypertension Epidemiology and Patient Population 8 Chronic Pulmonary Hypertension Patient Journey 9 Chronic Pulmonary Hypertension Treatment Algorithm, Chronic Pulmonary Hypertension Current Treatment, and Medical Practices 10 Key Endpoints in Chronic Pulmonary Hypertension Clinical Trials 11 Chronic Pulmonary Hypertension Marketed Therapies 12 Chronic Pulmonary Hypertension Emerging Therapies 13 Chronic Pulmonary Hypertension: 7 Major Market Analysis 14 Attribute analysis 15 Access and Reimbursement Overview of Chronic Pulmonary Hypertension 16 Chronic Pulmonary Hypertension Market Key Opinion Leaders Reviews 18 Chronic Pulmonary Hypertension Market Drivers 19 Chronic Pulmonary Hypertension Market Barriers 20 SWOT Analysis 21 Disclaimer 22 DelveInsight Capabilities 23 About DelveInsight Related Reports: Chronic Pulmonary Hypertension Epidemiology 2034 DelveInsight's "Chronic Pulmonary Hypertension - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Chronic Pulmonary Hypertension Pipeline 2024 "Chronic Pulmonary Hypertension Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pulmonary Hypertension market. A detailed picture of the Chronic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Pulmonary Hypertension treatment guidelines. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
